Funder: Vertex Pharmaceuticals
Due Dates: February 27, 2026 (Beta thalassemia and sickle cell disease ISS RFP)
Funding Amounts: No formal cap; budgets must represent fair market value and not exceed 35% overhead.
Summary: Supports independent, investigator-initiated research in cystic fibrosis, sickle cell disease, beta thalassemia, and pain (US only) aligned with Vertex’s scientific interests.
Key Information: Beta thalassemia and sickle cell disease proposals must be submitted by the fixed deadline; cystic fibrosis and pain proposals are accepted on a rolling basis.